LO-FEMENAL 21 TABLETS 300 MCG
NORGESTREL : 300 MCG ETHINYL ESTRADIOL : 30 MCG · DIN 02215640 · PFIZER CANADA ULC
Health Canada status: CANCELLED POST MARKET
What is LO-FEMENAL 21 TABLETS?
LO-FEMENAL 21 TABLETS 300 MCG contains NORGESTREL : 300 MCG ETHINYL ESTRADIOL : 30 MCG. It is listed in the Health Canada Drug Product Database under DIN 02215640, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Apr-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LO-FEMENAL 21 TABLETS used for?
LO-FEMENAL Tablets are indicated for conception control.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02215640 |
|---|---|
| Brand name | LO-FEMENAL 21 TABLETS |
| Generic / active ingredient | NORGESTREL : 300 MCG ETHINYL ESTRADIOL : 30 MCG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 300 MCG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03AA06 NORGESTREL AND ESTROGEN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Apr-2014 |
| Original market date | 1996-10-25 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02215640 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2215640 |
| Brand name | LO-FEMENAL 21 TABLETS |
| Active ingredient / INN | NORGESTREL : 300 MCG ETHINYL ESTRADIOL : 30 MCG |
| ATC code | G03AA06 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it administered?
One tablet daily for 21 days, followed by 7 days off (21-day regimen) or 7 days of inert tablets (28-day regimen). Start on Day 1, Day 5, or first Sunday of cycle.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard pharmaceutical storage typically 15-30°C).
How is it supplied?
Available in 21-day and 28-day regimens (21 white active tablets; 28-day pack includes 7 pink inert tablets).
Which pack is which?
| Strength on the label | 300 MCG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | Available in 21-day and 28-day regimens (21 white active tablets; 28-day pack includes 7 pink inert tablets). |
| Storage | Not explicitly stated in provided text (standard pharmaceutical storage typically 15-30°C). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Thrombophlebitis, thromboembolic disorders, cerebrovascular/coronary artery disease, liver disease/tumours, breast/estrogen-dependent carcinoma, undiagnosed vaginal bleeding, pregnancy.
Warnings and precautions
Cigarette smoking increases risk of serious cardiovascular side effects, especially in women over 35. Discontinue if thromboembolic disorders, visual defects, or severe migraines occur.
What can be used instead?
Other Canadian products sharing ATC code G03AA06 NORGESTREL AND ESTROGEN. 0 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OVRAL 21 | 50 MCG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02043033 |
| OVRAL 21 TAB | .25 MG | TABLET | WYETH LTD. | CANCELLED POST MARKET | DIN 00034207 |
| OVRAL 28 TABLETS | 250 MCG | TABLET | WYETH CANADA | CANCELLED POST MARKET | DIN 02043041 |
| OVRAL 28TAB | .25 MG | TABLET | WYETH LTD. | CANCELLED POST MARKET | DIN 00340766 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.